Single-cell Genomics Continues to Drive Growth at Fluidigm as Q1 Revenues Rise 33 Percent | GenomeWeb

Fluidigm said this week that single-cell genomics applications and production genotyping continued to serve as the primary growth drivers for the company, helping first-quarter revenues spike 33 percent year over year.

As in recent quarters, about 40 percent of Fluidigm's revenues were driven by single-cell genomics applications, an area that the company has embraced as its sweet spot in the last few years, CEO Gajus Worthington said during a conference call yesterday following the release of Fluidigm's financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.